Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2007 Jul;246(1):105-13.
doi: 10.1097/01.sla.0000262787.88639.2b.

Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma

Fritz C Eilber  1 , Murray F Brennan, Frederick R Eilber, Jeffery J Eckardt, Stephen R Grobmyer, Elyn Riedel, Charles Forscher, Robert G Maki, Samuel Singer
Affiliations
Multicenter Study

Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma

Fritz C Eilber et al. Ann Surg. 2007 Jul.

Abstract

Purpose: To determine if ifosfamide-based chemotherapy (IF) offers a survival benefit to adult patients with primary extremity synovial sarcoma.

Patients and methods: Prospectively collected patient data from 2 institutions was used to identify all adult patients (>or=16 years) with >or=5 cm, deep, primary, extremity, synovial sarcoma that underwent surgical treatment of cure from 1990 to 2002. A total of 101 patients were identified and the median follow-up for survivors was 58 months. Clinical, pathologic, and treatment variables were analyzed for disease-specific survival (DSS), distant recurrence-free survival (DRFS), and local recurrence-free survival (LRFS).

Results: Sixty-eight (67%) patients were treated with IF and 33 (33%) patients received no chemotherapy (NoC) for the primary tumor. The characteristics of the IF-treated patients [median tumor size = 7.2 cm; monophasic n = 46 (68%)] were similar to NoC patients [median tumor size = 7 cm; monophasic n = 23 (70%)]. The 4-year DSS of the IF-treated patients was 88% compared with 67% for the NoC patients (P = 0.01). Smaller size (HR = 0.3 per 5-cm decrease, P < 0.0001) and treatment with IF (HR = 0.3 compared with NoC, P = 0.007) were independently associated with an improved DSS. Treatment with IF was independently associated with an improved DRFS (HR = 0.4, P = 0.03) but not associated with an improved LRFS (P = 0.39).

Conclusion: Ifosfamide-based chemotherapy was associated with an improved DSS in adult patients with high-risk, primary, extremity, synovial sarcoma and should be considered in the treatment of such patients.

PubMed Disclaimer

Figures

None
FIGURE 1. Disease-specific survival by treatment.
None
FIGURE 2. Disease-specific survival by treatment and size.
None
FIGURE 3. Distant recurrence-free survival by treatment.
None
FIGURE 4. Local recurrence-free survival by treatment.
See this image and copyright information in PMC

References

    1. Brennan MF, Singer S, Maki RG, et al. Sarcomas of the soft tissues and bone. In: DeVita VT, Hellmann S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. 2005;35:1584.
    1. Eilber FC, Eilber FR. Soft tissue sarcoma. In: Cameron J., ed. Current Surgical Therapy, 7th ed. St. Louis: Mosby, 2001; 1213–1218.
    1. Singer S, Corson JM, Gonin R, et al. Prognostic factors predictive of survival and local recurrence for extremity soft tissue sarcoma. Ann Surg. 1994;219:165–173. - PMC - PubMed
    1. Pisters PWT, Leung DHY, Woodruff J, et al. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996;14:1679–1689. - PubMed
    1. Coindre JM, Terrier P, Bui NB, et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma: a study on 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol. 1996;14:869–877. - PubMed

Publication types

MeSH terms